Can haemochromatosis cause a fatty liver? This question arises frequently as both conditions affect liver health, yet their relationship is more complex than a simple cause-and-effect. Haemochromatosis, a genetic disorder causing excessive iron absorption, primarily damages the liver through iron deposition rather than fat accumulation. However, emerging evidence suggests iron overload may contribute to metabolic dysfunction that promotes hepatic steatosis. Understanding this interplay is crucial, as coexisting iron overload and fatty liver disease can accelerate liver damage and complicate management. This article explores the mechanisms linking these conditions, their impact on liver health, and evidence-based approaches to diagnosis, treatment, and prevention in UK clinical practice.

Understanding Haemochromatosis and Fatty Liver Disease

Haemochromatosis is a genetic disorder characterised by excessive iron absorption from the diet, leading to iron accumulation in various organs, particularly the liver, heart, pancreas, and joints. In the UK, hereditary haemochromatosis affects approximately 1 in 150 to 1 in 200 people of Northern European descent through C282Y homozygosity, making it one of the most common inherited conditions, though clinical penetrance is lower. The disorder is most frequently caused by mutations in the HFE gene, with the C282Y homozygous mutation being the most clinically significant variant.

The condition develops gradually as iron deposits build up over many years, typically manifesting in middle age. Without treatment, iron overload can cause serious organ damage and life-threatening complications. Early detection through family screening or incidental blood test findings is crucial for preventing irreversible damage.

Fatty liver disease, medically termed hepatic steatosis, occurs when fat accumulates in liver cells, affecting more than 5% of hepatocytes. This condition exists in two main forms: non-alcoholic fatty liver disease (NAFLD), associated with metabolic syndrome, obesity, and type 2 diabetes; and alcohol-related liver disease (ARLD), caused by excessive alcohol consumption. NAFLD is increasingly common in the UK, affecting approximately 25% of the adult population.

Whilst fatty liver disease and haemochromatosis are distinct conditions with different underlying mechanisms, they can coexist in the same patient. Understanding the relationship between iron overload and liver pathology is essential for healthcare professionals managing patients with either condition, as the presence of both can accelerate liver damage and complicate treatment strategies.

Can Haemochromatosis Cause a Fatty Liver?

The relationship between haemochromatosis and fatty liver disease is complex and not entirely straightforward. Haemochromatosis is not recognised as a primary cause of hepatic steatosis in the classical sense seen in NAFLD. The primary pathological process in haemochromatosis involves iron deposition rather than fat accumulation in hepatocytes.

However, there is emerging evidence suggesting that iron overload may contribute to metabolic dysfunction that can promote fat accumulation in the liver. Studies have demonstrated that excess iron can interfere with insulin signalling pathways, potentially leading to insulin resistance—a key driver of NAFLD. This metabolic disruption may create conditions favourable for hepatic steatosis to develop alongside iron accumulation.

It is important to distinguish haemochromatosis from dysmetabolic iron overload syndrome (DIOS), in which mild iron accumulation occurs secondary to metabolic syndrome and NAFLD. In DIOS, the metabolic dysfunction drives both steatosis and iron deposition, whereas in hereditary haemochromatosis, iron overload is the primary abnormality.

Patients with haemochromatosis may have coexisting risk factors for fatty liver disease, including:

• Type 2 diabetes: Haemochromatosis can damage pancreatic beta cells, leading to diabetes, which itself increases fatty liver risk

• Metabolic syndrome: Iron overload may contribute to metabolic abnormalities

• Obesity: Independent risk factor that may coincide with haemochromatosis

• Alcohol consumption: Can exacerbate both conditions

When both haemochromatosis and hepatic steatosis are present, they typically represent concurrent pathologies rather than one causing the other. However, the presence of both iron overload and hepatic steatosis can significantly worsen liver inflammation and fibrosis, accelerating progression to cirrhosis. Clinicians should systematically assess for metabolic risk factors when haemochromatosis is diagnosed and evaluate both conditions independently when assessing patients with abnormal liver function tests or metabolic disturbances.

How Iron Overload Affects Liver Health

The liver is the primary site of iron storage in the body and consequently bears the brunt of damage in haemochromatosis. Iron accumulation in hepatocytes triggers a cascade of pathological processes that progressively damage liver tissue through several mechanisms.

Oxidative stress represents the principal mechanism of iron-induced liver injury. Excess iron, particularly in its free ferrous form, participates in Fenton reactions that generate highly reactive hydroxyl radicals. These free radicals cause lipid peroxidation of cell membranes, damage to cellular proteins, and DNA strand breaks. The resulting oxidative damage leads to hepatocyte death and triggers inflammatory responses.

Hepatic stellate cell activation occurs as a consequence of ongoing liver injury. These cells, normally quiescent, transform into myofibroblasts that produce excessive collagen and extracellular matrix proteins. This fibrogenic response leads to progressive liver fibrosis, which can advance through stages from mild portal fibrosis to bridging fibrosis and ultimately cirrhosis. The fibrotic process is often irreversible once advanced stages are reached.

Inflammatory pathways are upregulated in response to iron-mediated cellular damage. Pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) are released, perpetuating liver inflammation and contributing to fibrosis progression. Whilst inflammatory activity usually improves after iron depletion, the risk of fibrosis progression persists if advanced fibrosis or cirrhosis is already established.

The progression of liver disease in haemochromatosis is variable and depends on iron burden, age at diagnosis, coexisting risk factors, and fibrosis stage. The natural history may include initial iron deposition without significant damage, followed by fibrosis, and in some cases cirrhosis. Patients with cirrhosis from haemochromatosis have a significantly increased risk of hepatocellular carcinoma (HCC), with annual incidence rates commonly reported as 2–6%. Importantly, HCC risk persists even after iron depletion in those with established cirrhosis, necessitating ongoing surveillance. Liver damage is often asymptomatic in early stages, emphasising the importance of screening and early intervention in at-risk individuals.

Symptoms and Diagnosis of Liver Complications

Early-stage liver involvement in haemochromatosis is typically asymptomatic, making opportunistic screening and clinical vigilance essential. As iron accumulation progresses, patients may develop non-specific symptoms that can easily be attributed to other conditions, delaying diagnosis.

Common presenting symptoms include:

• Chronic fatigue and lethargy: Often the earliest and most persistent complaint

• Right upper quadrant discomfort: May result from liver enlargement, though not all patients develop hepatomegaly

• Joint pain: Particularly affecting the hands, knees, and hips

• Skin hyperpigmentation: Bronze or grey discolouration, sometimes called "bronze diabetes"

• Loss of libido and erectile dysfunction: Due to pituitary iron deposition affecting hormone production

As liver disease advances to cirrhosis, patients may develop signs of hepatic decompensation including jaundice, ascites (abdominal fluid accumulation), peripheral oedema, easy bruising, and hepatic encephalopathy.

Diagnostic investigations for haemochromatosis and associated liver complications follow NICE Clinical Knowledge Summaries (CKS), British Society for Haematology (BSH), and European Association for the Study of the Liver (EASL) guidance and typically include:

Blood tests form the initial screening approach. Transferrin saturation exceeding 45% is the key discriminator for haemochromatosis. Serum ferritin levels above 300 μg/L in men or 200 μg/L in women, combined with raised transferrin saturation, strongly suggest iron overload. Abnormal results should be repeated to confirm, and secondary causes of hyperferritinaemia (inflammation, infection, malignancy, alcohol excess) should be excluded. Ferritin levels above 1000 μg/L are a red flag for advanced fibrosis risk and warrant urgent hepatology referral and liver fibrosis staging. Liver function tests (ALT, AST, ALP, bilirubin, albumin) assess hepatocellular damage and synthetic function. Genetic testing for HFE mutations (C282Y and H63D) confirms hereditary haemochromatosis.

Imaging studies have distinct roles: ultrasound assesses liver morphology and size; transient elastography (FibroScan) measures liver stiffness to stage fibrosis non-invasively; and MRI T2 or R2 sequences provide non-invasive hepatic iron quantification. Liver biopsy, whilst less commonly required now, may be considered in patients with advanced fibrosis, diagnostic uncertainty, or when coexisting liver disease is suspected, providing histological assessment of iron deposition, inflammation, and fibrosis stage.

Referral to hepatology is indicated for:

• Ferritin >1000 μg/L

• Persistently abnormal liver function tests

• Raised liver stiffness on transient elastography

• Suspected cirrhosis or advanced fibrosis

• Diagnostic uncertainty

Treatment Options for Haemochromatosis-Related Liver Damage

Therapeutic venesection (phlebotomy) remains the cornerstone treatment for haemochromatosis and is highly effective at removing excess iron and preventing disease progression. This treatment involves regular removal of blood, typically 400–500 ml weekly initially, which forces the body to mobilise stored iron to produce new red blood cells. Haemoglobin should be checked before each venesection session and the procedure withheld if levels are low.

The treatment protocol typically follows two phases:

Induction phase: Weekly venesection continues until serum ferritin falls below 50 μg/L, which may take several months to over a year depending on initial iron burden. Patients require monitoring of full blood count and ferritin levels every 3–4 venesections.

Maintenance phase: Once iron stores are depleted, lifelong maintenance venesection (typically 3–4 times yearly) prevents reaccumulation. The frequency is individualised based on ferritin and transferrin saturation monitoring, aiming to maintain ferritin levels between 50–100 μg/L.

For patients unable to tolerate venesection due to anaemia, cardiovascular disease, or poor venous access, iron chelation therapy with desferrioxamine or deferasirox may be considered. However, these agents are not licensed for haemochromatosis in the UK and their use is off-label and should be initiated only by specialists. Chelation is less effective and more expensive than phlebotomy and requires careful monitoring for adverse effects. Patients should report any suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

Management of established liver disease requires a multidisciplinary approach. Patients with cirrhosis or advanced fibrosis need regular surveillance for hepatocellular carcinoma with six-monthly ultrasound, as recommended by NICE. Alpha-fetoprotein (AFP) testing may be added according to local protocols. Endoscopic screening for oesophageal varices is indicated in cirrhotic patients to prevent variceal bleeding, with risk stratification using Baveno VI criteria to identify those who may safely avoid endoscopy.

Lifestyle modifications are crucial adjuncts to medical treatment:

• Alcohol moderation or abstinence: Follow UK Chief Medical Officer low-risk drinking guidelines (≤14 units per week, spread over 3 or more days) if no fibrosis; abstain completely if advanced fibrosis or cirrhosis is present

• Dietary advice: Avoid iron supplements and high-dose vitamin C supplements; no strict iron restriction or routine limitation of red meat is necessary; avoid raw shellfish due to severe infection risk in iron overload; consider drinking tea or coffee with meals to reduce iron absorption

• Proton pump inhibitors (PPIs): May be considered as an adjunct to reduce non-haem iron absorption in selected patients, per EASL guidance

• Hepatitis vaccination: Hepatitis A and B vaccines are recommended for all patients with chronic liver disease, following UKHSA Green Book guidance

Liver transplantation may be necessary for patients with decompensated cirrhosis or hepatocellular carcinoma meeting transplant criteria. Outcomes are generally favourable, though haemochromatosis management must continue post-transplant.

Preventing Liver Disease in Haemochromatosis Patients

Early diagnosis and treatment initiation are paramount in preventing irreversible liver damage in haemochromatosis. Studies demonstrate that patients who begin treatment before developing cirrhosis have a normal life expectancy, whilst those with established cirrhosis face significantly increased morbidity and mortality.

Family screening represents a crucial preventive strategy. Adult first-degree relatives of patients with confirmed p.C282Y homozygous haemochromatosis should be offered HFE genotyping directly, rather than waiting for abnormal iron studies. This cascade screening approach, supported by the NHS, enables identification of at-risk individuals before symptoms develop and allows early intervention.

Regular monitoring for patients with confirmed haemochromatosis includes:

• Ferritin and transferrin saturation: Every 3–6 months during maintenance therapy

• Liver function tests: Annually or more frequently if abnormal

• Diabetes screening: Annual HbA1c or fasting glucose

• Hepatocellular carcinoma surveillance: Six-monthly ultrasound (with or without AFP per local policy) for patients with cirrhosis or advanced fibrosis; not required for all patients

Patient education empowers individuals to actively participate in their care. Patients should understand the importance of treatment adherence, recognise symptoms requiring urgent medical attention, and avoid factors that exacerbate liver damage.

When to contact your GP:

• New or worsening abdominal pain or swelling

• Yellowing of skin or eyes (jaundice)

• Unexplained weight loss

• Persistent nausea or vomiting

• Confusion or personality changes

• Dark urine or pale stools

When to seek same-day assessment or call 999:

• Vomiting blood or coffee-ground material

• Black, tarry stools (melaena)

• Severe drowsiness or confusion

• Rapidly increasing abdominal swelling

• Fever with abdominal pain

For patients with concurrent fatty liver disease risk factors, weight management through diet and exercise is essential. A Mediterranean-style diet rich in vegetables, whole grains, and healthy fats, combined with regular physical activity, can improve hepatic steatosis independently of iron management. Optimising control of diabetes, hypertension, and dyslipidaemia further reduces liver disease progression risk, creating a comprehensive approach to hepatic health preservation.

Frequently Asked Questions